Company news
Neurizon Therapeutics Limited news in 2024
Neurizon Therapeutics Limited's news releases, calls and decks from 2024, newest first.
Neurizon Files IND Application to Support HEALEY ALS Trial
December 17, 2024
Neurizon Granted OMPD for NUZ-001 in Europe
December 16, 2024
Positive 8-month Interim Data from OLE Study
December 15, 2024
Neurizon Receives Additional R&D Tax Incentive Rebate
December 11, 2024
Neurizon Presents Positive Preclinical Data on NUZ-001
November 14, 2024
NUZ-001 Reduces Aggregation of Key ALS Disease Target
November 14, 2024
Positive opinion received on OMPD for NUZ-001 in Europe
November 10, 2024
PharmAust Receives R&D Tax Incentive Rebate
October 8, 2024
Appendix 4E and 2024 Annual Report
August 30, 2024
Positive Interim Study Results from OLE Study in ALS
August 25, 2024
PharmAust Completes Share Purchase Plan
July 23, 2024
Monepantel Selected for Entry into HEALEY ALS Platform Trial
July 14, 2024
Share Purchase Plan Offer Booklet
June 27, 2024
PharmAust raises $10 million via Placement and announces SPP
June 20, 2024
OLE Study update reveals impressive Survival Data
June 4, 2024
Executive team strengthened, appointment of MD/CEO & new CSO
May 30, 2024
PharmAust receives Orphan Drug Designation for monepantel
May 17, 2024
Board Changes
May 8, 2024
Resignation of Dr Michael Thurn & appointment of John Clark
April 22, 2024
Final Ethics Approval for Open-Label MND Extension Study
April 10, 2024
Media clarification
April 2, 2024
Pause in Trading
April 1, 2024
Positive clinical data filed with FDA to support ODD request
March 13, 2024
Appendix 4D & Half-Year Report
February 29, 2024
Positive Phase 1 MEND Study Top-Line Results
February 27, 2024
Presentation - Phase 1 Top-Line Results
February 27, 2024
PharmAust Forms World-Class Scientific Advisory Board
February 21, 2024
FDA Outlines Pathway to Accelerated Approval for MPL in MND
February 15, 2024
Extension Study Begins, Analysis Suggests Survival Benefit
February 13, 2024
Ethics Committee Approval for Open-Label MND Extension Study
January 29, 2024
FDA Provides Clear Feedback for ODD Approval
January 28, 2024
PharmAust Partners with Berry Consultants for MND Phase 2/3
January 15, 2024
FDA Grants PharmAust Pre-IND Meeting
January 1, 2024
Decks in 2024
- Technical Presentation (February 2024)
Technical · 16 slides · Feb 27, 2024